Allogeneic bone marrow transplantation (BMT) from a genotypically identical family donor is an accepted therapeutic option for homozygous beta-thalassemia. However, only a minority of patients have access to this curative procedure. The aim of this study is to explore the feasibility of matched unrelated transplants in thalassemia and the possibility of reducing the risk of immunologic complications through careful selection of donor/recipient pairs. Since November 1992, 32 patients (age range, 2-28 years) have been enrolled. There were 4 patients assigned to risk-class I, 11 to risk-class II, and 17 to risk-class III of the Pesaro classification. Extended haplotype analysis and family segregation studies were employed for identification of suitable donors. Of the 32 donor/recipient pairs, 24 were identical for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, and DQB1 loci; 7 pairs were identical for 2 extended haplotypes, and 15 pairs shared one extended haplotype. Grade II-IV acute graft-versus-host disease (GVHD) developed in 11 cases (41%) and chronic GVHD in 6 (25%) out of 24 patients at risk. There are 22 patients (69%) who are alive and transfusion-independent after a median follow-up of 30 months (range, 7-109 months). There were 6 patients (19%) who engrafted and subsequently died from transplant-related complications. In 4 cases (12.5%) graft rejection was observed within 30 days and it was followed by autologous reconstitution. Out of 22 patients with a donor identical for at least one extended haplotype, there are 19 who survived, 17 of them being transfusion-independent. Among the 10 recipients who did not share any extended haplotype with the donor, only 5 are alive without thalassemia and 3 patients died. Of the 6 patients who died, 5 belonged to risk-class III and only 1 to risk-class II. BMT from well-selected unrelated donors may offer results comparable to those obtained in transplantations using HLA-identical family donors, especially for patients with lesser iron overload.

Introduction

Allogeneic bone marrow transplantation (BMT) from a genotypically identical family donor has radically changed the prognosis of patients with homozygous beta-thalassemia. For young patients at an early stage of disease, the reported percentage of thalassemia-free survival and the mortality risk were 91% and 8%, respectively.1,2 Transplantation performed on older, heavily iron-loaded patients, in particular those with liver abnormalities, has a less-satisfactory outcome, the probability of thalassemia-free survival and mortality being 51% and 32%, respectively.3 

The probability of finding an HLA-identical donor within the family is less than 30% in western countries.4 For the remaining 70% of patients with thalassemia, there was until recently no option other than treatment based on chronic transfusion and iron-chelating therapy. Although optimization of protocols for transfusion and chelation has dramatically improved the life expectancy of these patients, complications of iron overload cannot be completely avoided.5,6 Full compliance with a chronic transfusion regimen and a daily, lifelong injective chelation therapy has been shown to be difficult to maintain with advancing age.7Multiple endocrine dysfunctions, myocardiopathy, progressive liver fibrosis, and consequences of posttransfusion viral infections affect the quality of life and increase the mortality risk with age.7-9 

During the past 10 years, BMT from unrelated donors has been increasingly employed for hematologic malignancies and life-threatening inborn errors.10-12 At first, results were characterized by elevated mortality due to the high frequency of transplantation-related complications, mainly acute and chronic graft-versus-host disease (GVHD) and graft failure. These complications were most likely related to HLA differences either not tested or not revealed by the techniques for HLA typing available at that time.13-15 Therefore, BMT with volunteer unrelated donors for beta-thalassemia did not meet consensus, due to the high risk of transplantation-related death.

Recent years have witnessed a progressive increment in the number of unrelated-donor BMTs, mainly due to the increase in the number of volunteer donors worldwide; some studies have reported results comparable to those obtained in transplantations using HLA-matched family donors, and this improvement may be attributed to the introduction of high-resolution molecular techniques for histocompatibility testing.16-20 

There is increasing evidence that the entire structure of an HLA extended or ancestral haplotype is generally identical, except for rare variations at the centromeric and telomeric extremities, in HLA-matched unrelated individuals belonging to the same or a different ethnic group.21 Therefore, 2 extended haplotypes shared by donor and recipient guarantee a very high probability of identity of the 2 HLA regions both for the typed A, B, C, DR, and DQ genes and for the nucleotide sequences between these genes where there may be polymorphism, potentially relevant to BMT. Moreover, several studies support the hypothesis that reduction of posttransplantation immune-mediated complications is attained when donor/recipient pairs share one or 2 extended haplotypes.22-24 

We conducted a pilot study, approved by the Italian Bone Marrow Transplant Group (GITMO) and by the Italian Bone Marrow Donor Registry (IBMDR), aimed at exploring both the feasibility of BMT from a marrow unrelated donor (MUD) in thalassemia and the possibility of reducing the risk of immunologic complications by selecting donor/recipient pairs sharing extended haplotypes or parts of them.

Patients, materials, and methods

Clinical characteristics of patients

From November 1992 to May 2001, 32 patients with thalassemia major were enrolled into this study by 4 BMT centers in Italy. The study received approval by the local institutional review board. After detailed explanation of the procedure and its risks, informed consent was obtained from all patients or from parents in the case of minors. Particular emphasis was placed on the option of continuing conventional disease management with transfusions and chelation therapy. Pretransplantation patient characteristics are shown in Table1. There were 11 female patients and 21 male patients, age range being 2-28 years (median, 14 years).

Table 1.

Patient and donor data, transplantation regimen, and outcome

Patient no. Patient sex/age Donor sex/age Iron chelation Portal fibrosis Liver iron grade (ciot) Risk class Conditioning regimen Cellular dose NC × 108/kg Take aGVHD grade cGVHD grade Outcome 
1* F/17 F/42 Ir MO III III BU14-CY160 3.9 Yes Alive with graft 
2 M/9 F/44 MI II II BU14-CY160 2.6 No NE NE Alive with thalassemia 
3* M/4 F/32 – – BU14-CY200 1.9 Yes Alive with graft 
M/7 F/31 Ir MO II III BU14-CY200 4.0 No NE NE Alive with thalassemia 
5 F/9 M/37 Ir MO II II BU14-TT10-CY200 5.8 Yes II Alive with graft 
F/15 M/36 MI II II BU14-TT10-CY200 2.6 Yes III Alive with graft 
7 M/16 M/32 Ir MI II III BU14-TT10-CY160 3.0 Yes II Alive with graft 
M/19 M/35 Ir SE IV III BU14-TT10-CY160 3.9 Yes II Died (day + 470) 
9 M/17 M/36 Ir MO III III BU14-TT10-CY160 2.3 Yes Alive with graft 
10* F/12 M/38 MI II II BU14-TT10-CY200 4.2 Yes Alive with graft 
11 M/18 F/40 Ir SE IV III BU14-TT10-CY160 2.9 Yes II Died (day + 125) 
12* M/6 M/43 MI II BU14-TT10-CY200 5.8 Yes Alive with graft 
13* M/14 F/30 MI II II BU14-TT10-CY200 3.4 Yes NE Died (day + 64) 
14 M/6 F/41 Ir SE IV III BU14-TT10-CY160 I0.0 No NE NE Alive with thalassemia 
15 M/25 F/34 Ir SE IV III BU14-TT10-CY120 3.5 Yes IV Alive with graft 
16 F/15 F/39 Ir MO III III BU14-TT10-CY160 1.8 Yes III NE Died (day + 66) 
17 M/5 F/45 MO II II BU14-TT10-CY200 3.9 Yes Alive with graft 
18 F/2 F/25 NO BU14-TT10-CY200 5.5 Yes II Alive with graft 
19 F/13 M/36 MO II II BU14-TT10-CY200 2.6 Yes Alive with graft 
20* M/15 M/26 MI II II BU14-TT10-CY200 4.5 No NE NE Alive with thalassemia 
21 F/28 F/31 Ir SE III III BU14-TT10-CY120 3.7 Yes II Alive with graft 
22 F/26 M/34 Ir SE III III BU14-TT10-CY120 3.7 Yes NE NE Died (day + 17) 
23* F/15 M/36 MI II BU14-TT10-CY200 4.1 Yes Alive with graft 
24 M/26 F/39 Ir MI III III BU14-TT10-CY120 7.5 Yes Alive with graft 
25 M/24 M/50 Ir MO III III BU14-TT10-CY120 3.3 Yes IV Died (day + 269) 
26 F/18 M/33 Ir MO III III BU14-TT10-CY160 3.8 Yes Alive with graft 
27 M/11 F/25 MI II II BU14-TT10-CY200 3.9 Yes Alive with graft 
28 M/7 M/30 NO BU14-TT10-CY200 7.0 Yes Alive with graft 
29 M/14 M/52 MI II III BU14-TT10-CY200 3.0 Yes III Alive with graft 
30 M/21 M/36 Ir MO III III BU14-TT10-CY120 3.8 Yes Alive with graft 
31 M/4 F/31 NO BU14-TT10-CY200 4.0 Yes Alive with graft 
32 M/16 F/43 Ir SE IV III BU14-TT10-CY160 I1.6 Yes Alive with graft 
Patient no. Patient sex/age Donor sex/age Iron chelation Portal fibrosis Liver iron grade (ciot) Risk class Conditioning regimen Cellular dose NC × 108/kg Take aGVHD grade cGVHD grade Outcome 
1* F/17 F/42 Ir MO III III BU14-CY160 3.9 Yes Alive with graft 
2 M/9 F/44 MI II II BU14-CY160 2.6 No NE NE Alive with thalassemia 
3* M/4 F/32 – – BU14-CY200 1.9 Yes Alive with graft 
M/7 F/31 Ir MO II III BU14-CY200 4.0 No NE NE Alive with thalassemia 
5 F/9 M/37 Ir MO II II BU14-TT10-CY200 5.8 Yes II Alive with graft 
F/15 M/36 MI II II BU14-TT10-CY200 2.6 Yes III Alive with graft 
7 M/16 M/32 Ir MI II III BU14-TT10-CY160 3.0 Yes II Alive with graft 
M/19 M/35 Ir SE IV III BU14-TT10-CY160 3.9 Yes II Died (day + 470) 
9 M/17 M/36 Ir MO III III BU14-TT10-CY160 2.3 Yes Alive with graft 
10* F/12 M/38 MI II II BU14-TT10-CY200 4.2 Yes Alive with graft 
11 M/18 F/40 Ir SE IV III BU14-TT10-CY160 2.9 Yes II Died (day + 125) 
12* M/6 M/43 MI II BU14-TT10-CY200 5.8 Yes Alive with graft 
13* M/14 F/30 MI II II BU14-TT10-CY200 3.4 Yes NE Died (day + 64) 
14 M/6 F/41 Ir SE IV III BU14-TT10-CY160 I0.0 No NE NE Alive with thalassemia 
15 M/25 F/34 Ir SE IV III BU14-TT10-CY120 3.5 Yes IV Alive with graft 
16 F/15 F/39 Ir MO III III BU14-TT10-CY160 1.8 Yes III NE Died (day + 66) 
17 M/5 F/45 MO II II BU14-TT10-CY200 3.9 Yes Alive with graft 
18 F/2 F/25 NO BU14-TT10-CY200 5.5 Yes II Alive with graft 
19 F/13 M/36 MO II II BU14-TT10-CY200 2.6 Yes Alive with graft 
20* M/15 M/26 MI II II BU14-TT10-CY200 4.5 No NE NE Alive with thalassemia 
21 F/28 F/31 Ir SE III III BU14-TT10-CY120 3.7 Yes II Alive with graft 
22 F/26 M/34 Ir SE III III BU14-TT10-CY120 3.7 Yes NE NE Died (day + 17) 
23* F/15 M/36 MI II BU14-TT10-CY200 4.1 Yes Alive with graft 
24 M/26 F/39 Ir MI III III BU14-TT10-CY120 7.5 Yes Alive with graft 
25 M/24 M/50 Ir MO III III BU14-TT10-CY120 3.3 Yes IV Died (day + 269) 
26 F/18 M/33 Ir MO III III BU14-TT10-CY160 3.8 Yes Alive with graft 
27 M/11 F/25 MI II II BU14-TT10-CY200 3.9 Yes Alive with graft 
28 M/7 M/30 NO BU14-TT10-CY200 7.0 Yes Alive with graft 
29 M/14 M/52 MI II III BU14-TT10-CY200 3.0 Yes III Alive with graft 
30 M/21 M/36 Ir MO III III BU14-TT10-CY120 3.8 Yes Alive with graft 
31 M/4 F/31 NO BU14-TT10-CY200 4.0 Yes Alive with graft 
32 M/16 F/43 Ir SE IV III BU14-TT10-CY160 I1.6 Yes Alive with graft 
*

Patient shared 2 extended haplotypes.

Patient shared one extended haplotype.

Take followed by rejection.

aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; R, regular; Ir, irregular; NO, none; MI, mild; MO, moderate; SE, severe; BU, busulphan; CY, cyclophosphamide; TT, thiotepa; NC, nucleated cells; NE, not evaluable; L, limited; E, extensive.

Prior to transplantation, all patients underwent a complete check-up and were assigned to one of 3 classes of risk according to the criteria proposed by Lucarelli et al.25 Risk factors were (1) hepatomegaly, (2) liver biopsy revealing the presence of portal fibrosis, and (3) the quality of pretransplantation iron chelation.

The classification of liver iron overload was based on the scheme of Sciot and portal fibrosis was defined in each patient as mild, moderate, or severe.26 

One patient, aged 4 years, did not undergo liver biopsy because his parents refused the procedure and he was assigned to risk-class I for the absence of the other 2 risk factors.

Of 32 patients, 8 were positive for hepatitis C virus (HCV)–RNA and 2 of them had antibodies to hepatitis B virus due to previous clinical infection.

In 3 HCV-RNA–positive patients, liver histology revealed chronic active hepatitis. In the remaining 5 patients, liver biopsy indicated a diagnosis of chronic persistent hepatitis. There were 24 patients who had positive cytomegalovirus (CMV) serology.

Out of 32 patients examined, 4 were assigned to risk-class I, 11 to risk-class II, and 17 to risk-class III.

HLA typing and donor/recipient matching

Patients, donors and, when feasible, family members were typed for the currently recognized HLA-A, -B, and -Cw antigens using mono-oligospecific antisera according to a standard 2-stage National Institutes of Health (NIH) complement-dependent microcytotoxicity test. Typing for HLA-DR and -DQ was performed using Dynabead-purified B cells in a microcytotoxicity assay.

DNA for molecular typing was extracted from whole blood collected in neuroaminidase-treated ethylenediaminetetracetic acid (EDTA). Alleles at the HLA-A, -B, -Cw, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, and -DPB1 loci were identified by polymerase chain reaction–single strand polymorphism (PCR-SSP) (Dynal, Oslo, Norway) and sequence-based typing. Amplification and sequencing of HLA class I and class II genes were performed as previously described,27-30 using standard big dye terminator cycle-sequencing chemistry supplied with the ABI sequencing kit. Reactions were analyzed on the Applied Biosystem 310 Automated DNA sequencer (Applied Biosystems, Foster City, CA). Alleles were assigned according to DNA sequences published by the “Nomenclature for the Factors of HLA System” Committee.31 

Class III HLA antigens C4A and C4B were determined by immunofixation electrophoresis of neuroaminidase-treated EDTA plasma.32 

Bf alleles were determined by high-voltage electrophoresis in agarose gel, followed by immunofixation with anti–human factor B antibodies.33 

Extended or ancestral haplotypes

The combination of alleles encoded by 2 or more HLA loci on a single chromosome is defined as a haplotype. Because certain alleles are strongly associated with one another due to linkage disequilibrium (LD), only a relatively small number of haplotypes can be observed. The HLA haplotypes that show a high LD among their class I, class II, and class III alleles are considered extended or ancestral haplotypes.21 These haplotypes are conserved and therefore can be shared by apparently unrelated subjects.22Therefore, 2 unrelated individuals who share 2 extended haplotypes are highly likely to be identical, not only for the routinely tested HLA class I and class II genes, but for the entire major histocompatibility (MHC) region where there are many other genes that have an important role in antigen presentation and immune response. Several mechanisms, including selection pressure, recombination suppression, and preferential transmission, may explain the conservation and frequency of extended or ancestral haplotypes in the different populations.34 In our study, HLA extended haplotypes were identified and defined by referring to the data provided by Rendine et al35 and Contu et al36 for the Italian population and to data from the 10th and 11th International Histocompatibility Workshop and the National Marrow Donor Program (NMDP) donor registry for other populations37,39(Tables 2,3).

Table 2.

HLA haplotypes of the 32 unrelated bone marrow transplant pairs

 Patient/donor HLA-A Cw DRB1 DPB1 
1* 3002/3002 0501/0501 1801/1801 03011/03011 0301/0301 
 CA01-705802 "/" "/" "/" "/" "/" 
2 3002/1103 0501/0401 1801/3501 03011/1401 0401/1001 
 CA01-704602 "/" "/" "/" "/" "/0301 
3* 3002/0201 0501/0501 1801/1801 03011/03011 0301/0301 
 CA01-709970 "/" "/" "/" "/" "/" 
1101/0205 0701/0401 1801/3501 1601/0301 0401/1401 
 CA01-710618 "/0201 0202/" "/" "/" 0201/0301 
5 3002/2601 0501/1203 1801/3801 03011/0405 0401/2401 
 CA01-710357 "/" "/" "/" "/" "/0301 
3002/2402 0701/1203 5801/1801 1601/1104 0401/0401 
 CA01-707391 "/2403 "/" "/" "/" "/0402 
7 0201/0201 0501/0202 1801/5101 03011/1601 0201/0202 
 VI01-27 "/" "/1402 "/" "/" 0401/1101 
0205/1101 0701/0401 4901/3501 0405/1601 0201/0201 
 CA01-709735 "/" "/" "/" "/" "/0401 
9 0205/3201 0701/0801 5801/1402 1601/0701 0201/1701 
 CA01-712211 "/" "/" "/" "/" "/" 
10* 10 0101/0205 0602/0701 3701/5801 1001/1601 0201/0402 
 CA01-713527 "/" "/" "/" "/" "/0401 
11 11 3201/0205 0202/0701 1801/5801 0301/1601 0401/0201 
 NU01-436 "/" "/" "/" "/" "/" 
12* 12 3002/0201 0501/02021 1801/2705 03011/1601 0301/0402 
 NU01-208 "/" "/" "/" "/" "/" 
13* 13 3002/0101 0501/0602 1801/3701 03011/1001 0301/0201 
 SS02-271 "/" "/" "/" "/" 0201/" 
14 14 0201/1101 0702/1502 5101/07021 1101/1301 0402/4601 
 FLY-08021 "/" "/1402 "/" "/" "/0201 
15 15 1101/0201 0401/0202 3501/1801 0101/0301 0402/0402 
 CA01-706695 "/" "/" 3503/" "/" 0401/0301 
16 16 0201/0301 0701/0401 5001/3501 0701/1104 0201/1101 
 1021461 "/" 0602/" "/" "/" "/0201 
17 17 0205/1101 0701/0303 5801/5501 1601/1401 0401/0402 
 SS01-369 "/" "/" "/" "/" "/" 
18 18 2402/3002 1203/0501 1801/1801 1104/0301 2012/2012 
 CA01-707647 "/" "/" "/" "/" 0301/0402 
19 19 0201/1101 0401/0401 3501/3501 1401/1401 0401/0401 
 GE01-22298 "/" "/" "/" "/" "/0101 
20* 20 0205/0101 0701/0701 5801/0801 1601/0301 0401/0201 
 CA01-712502 "/" "/" "/" "/" 0301/" 
21 21 3002/0301 0501/0401 1801/3501 03011/1401 0401/0401 
 CR01-290 "/" "/" "/" "/" "/0301 
22 22 0205/2402 0701/1203 5801/1801 1601/1104 0401/1101 
 CA01-710090 "/" "/" "/" "/" "/0402 
23* 23 0205/3301 0701/0801 5801/1402 1601/0102 0301/02012 
 CA01-707336 "/" "/" "/" "/" "/" 
24 24 2301/3201 04011/0701 3502/4901 11041/11041 0401/0402 
 AL01-3173 "/" "/" 3501/" "/" "/" 
25 25 2402/3002 0501/0802 1402/51011 1201/0102 0401/0401 
 SS01-507 "/" "/" "/" "/" "/" 
26 26 0201/1101 0701/0801 1801/1402 1104/0102 0401/0402 
 MI03-941 "/" "/" "/" "/" "/" 
27 27 3002/3201 0501/0102 1801/5501 0301/1401 0201/0401 
 CA01-715847 "/" "/" "/" "/" 0301/0401 
28 28 0201/0301 0501/0701 4402/4901 1101/1104 0401/0402 
 DKM-837594 "/" 0501/0202 "/" "/" "/" 
29 29 3002/2402 0501/0702 1801/4501 0301/1103 0301/0401 
 CA01-710134 "/" "/" "/" "/" "/" 
30 30 0201/1101 0701/03031 1801/15011 1104/1101 0301/0402 
 DKM-913837 "/" "/" "/" "/" "/" 
31 31 3002/2601 0501/0702 1801/0801 0301/0301 0401/0401 
 CA01-713577 "/" "/" "/" "/" 0401/0402 
32 32 0101/3301 0602/0801 5701/1402 1601/0102 0301/0401 
 CT02–234 "/" "/" "/" "/" "/" 
 Patient/donor HLA-A Cw DRB1 DPB1 
1* 3002/3002 0501/0501 1801/1801 03011/03011 0301/0301 
 CA01-705802 "/" "/" "/" "/" "/" 
2 3002/1103 0501/0401 1801/3501 03011/1401 0401/1001 
 CA01-704602 "/" "/" "/" "/" "/0301 
3* 3002/0201 0501/0501 1801/1801 03011/03011 0301/0301 
 CA01-709970 "/" "/" "/" "/" "/" 
1101/0205 0701/0401 1801/3501 1601/0301 0401/1401 
 CA01-710618 "/0201 0202/" "/" "/" 0201/0301 
5 3002/2601 0501/1203 1801/3801 03011/0405 0401/2401 
 CA01-710357 "/" "/" "/" "/" "/0301 
3002/2402 0701/1203 5801/1801 1601/1104 0401/0401 
 CA01-707391 "/2403 "/" "/" "/" "/0402 
7 0201/0201 0501/0202 1801/5101 03011/1601 0201/0202 
 VI01-27 "/" "/1402 "/" "/" 0401/1101 
0205/1101 0701/0401 4901/3501 0405/1601 0201/0201 
 CA01-709735 "/" "/" "/" "/" "/0401 
9 0205/3201 0701/0801 5801/1402 1601/0701 0201/1701 
 CA01-712211 "/" "/" "/" "/" "/" 
10* 10 0101/0205 0602/0701 3701/5801 1001/1601 0201/0402 
 CA01-713527 "/" "/" "/" "/" "/0401 
11 11 3201/0205 0202/0701 1801/5801 0301/1601 0401/0201 
 NU01-436 "/" "/" "/" "/" "/" 
12* 12 3002/0201 0501/02021 1801/2705 03011/1601 0301/0402 
 NU01-208 "/" "/" "/" "/" "/" 
13* 13 3002/0101 0501/0602 1801/3701 03011/1001 0301/0201 
 SS02-271 "/" "/" "/" "/" 0201/" 
14 14 0201/1101 0702/1502 5101/07021 1101/1301 0402/4601 
 FLY-08021 "/" "/1402 "/" "/" "/0201 
15 15 1101/0201 0401/0202 3501/1801 0101/0301 0402/0402 
 CA01-706695 "/" "/" 3503/" "/" 0401/0301 
16 16 0201/0301 0701/0401 5001/3501 0701/1104 0201/1101 
 1021461 "/" 0602/" "/" "/" "/0201 
17 17 0205/1101 0701/0303 5801/5501 1601/1401 0401/0402 
 SS01-369 "/" "/" "/" "/" "/" 
18 18 2402/3002 1203/0501 1801/1801 1104/0301 2012/2012 
 CA01-707647 "/" "/" "/" "/" 0301/0402 
19 19 0201/1101 0401/0401 3501/3501 1401/1401 0401/0401 
 GE01-22298 "/" "/" "/" "/" "/0101 
20* 20 0205/0101 0701/0701 5801/0801 1601/0301 0401/0201 
 CA01-712502 "/" "/" "/" "/" 0301/" 
21 21 3002/0301 0501/0401 1801/3501 03011/1401 0401/0401 
 CR01-290 "/" "/" "/" "/" "/0301 
22 22 0205/2402 0701/1203 5801/1801 1601/1104 0401/1101 
 CA01-710090 "/" "/" "/" "/" "/0402 
23* 23 0205/3301 0701/0801 5801/1402 1601/0102 0301/02012 
 CA01-707336 "/" "/" "/" "/" "/" 
24 24 2301/3201 04011/0701 3502/4901 11041/11041 0401/0402 
 AL01-3173 "/" "/" 3501/" "/" "/" 
25 25 2402/3002 0501/0802 1402/51011 1201/0102 0401/0401 
 SS01-507 "/" "/" "/" "/" "/" 
26 26 0201/1101 0701/0801 1801/1402 1104/0102 0401/0402 
 MI03-941 "/" "/" "/" "/" "/" 
27 27 3002/3201 0501/0102 1801/5501 0301/1401 0201/0401 
 CA01-715847 "/" "/" "/" "/" 0301/0401 
28 28 0201/0301 0501/0701 4402/4901 1101/1104 0401/0402 
 DKM-837594 "/" 0501/0202 "/" "/" "/" 
29 29 3002/2402 0501/0702 1801/4501 0301/1103 0301/0401 
 CA01-710134 "/" "/" "/" "/" "/" 
30 30 0201/1101 0701/03031 1801/15011 1104/1101 0301/0402 
 DKM-913837 "/" "/" "/" "/" "/" 
31 31 3002/2601 0501/0702 1801/0801 0301/0301 0401/0401 
 CA01-713577 "/" "/" "/" "/" 0401/0402 
32 32 0101/3301 0602/0801 5701/1402 1601/0102 0301/0401 
 CT02–234 "/" "/" "/" "/" "/" 
*

Pairs shared two extended haplotypes.

Pairs shared one extended haplotype.

The alleles (not listed) at loci HLA-DRB3, -DRB4, -DRB5, -DQA1 and -DQB1 were identical in all donor/recipient pairs. The differences found at the other loci are given in bold print.

Table 3.

List of the HLA extended haplotypes found in the 22 unrelated donor/recipient pairs

Extended haplotypes Numbers shared Race 
HLA-A30-Cw5-B18-DR3 123-150 C, S 
HLA-A2-Cw7-B58-DR2 C, S  
HLA-A2-Cw5-B18-DR3 C, S 
HLA-A1-Cw6-B37-DR10 C, S, A 
HLA-A33-Cw8-B14-DR1 C, S  
HLA-A2-Cw7-B18-DR5 C, S  
HLA-A1-Cw7-B8-DR3 C  
HLA-A2-Cw2-B27-DR2 C, S 
Extended haplotypes Numbers shared Race 
HLA-A30-Cw5-B18-DR3 123-150 C, S 
HLA-A2-Cw7-B58-DR2 C, S  
HLA-A2-Cw5-B18-DR3 C, S 
HLA-A1-Cw6-B37-DR10 C, S, A 
HLA-A33-Cw8-B14-DR1 C, S  
HLA-A2-Cw7-B18-DR5 C, S  
HLA-A1-Cw7-B8-DR3 C  
HLA-A2-Cw2-B27-DR2 C, S 

C indicates Caucasian; S, Sardinian; A, Asian (ethnic groups in which these haplotypes are found in linkage disequilibrium).

F3-150

One donor/recipient pair was homozygous for this haplotype.

Donor characteristics

There were 29 bone marrow donors identified within the IBMDR, 2 were found in the German National Bone Marrow Donor Registry, and one was found in the French Bone Marrow Donor Registry. Median interval between donor search and transplantation was 5 months (interval from 1 to 20 months). There were 16 female donors and 16 male donors, age range being 25 to 52 years (median, 36 years). For 24 donors, at least one informative family member was typed for HLA haplotype deduction. In the remaining 8 cases, the haplotypes were assigned on the basis of the presence of at least one extended haplotype well-defined in the population.35-39 Of these 8 cases, 4 could be considered to share a single extended haplotype with the patients: HLA-A2, Cw5, B18, and DR3 for pair no. 7; HLA-A30, Cw5, B18, and DR3 for pair no. 21; and HLA-A2, Cw7, B18, and DR5 for pair nos. 26 and 30. The first 2 haplotypes are in strong LD in the Sardinian population, the third haplotype is in LD in the Greek and Sardinian populations35-39 (Tables 2, 3).

Transplantation regimen, GVHD prophylaxis, and supportive therapy

Data regarding conditioning regimen and number of cells infused are given in Table 1. The first 4 patients received transplants after a preparative regimen including busulfan (BU) and cyclophosphamide (CY). Oral BU (3.5 mg/kg per day), was administered 3 times per day for 4 days (total dose 14 mg/kg) followed by 50 mg/kg per day intravenous CY for 4 days (total dose 200 mg/kg) in 2 patients and 40 mg/kg per day CY for 4 days (total dose 160 mg/kg) in the other 2 patients. As 2 of these 4 patients did not have sustained engraftment, in the remaining 28 patients the conditioning regimen was modified as follows: 14 mg/kg BU, 10 mg/kg thiotepa (TT), and 200 mg/kg CY for 14 patients (risk classes I and II); 14 mg/kg BU, 10 mg/kg TT, and 160 mg/kg CY for 8 patients aged less than 16 (risk class III); 14 mg/kg BU, 10 mg/kg TT, and 120 mg/kg CY for 6 patients aged more than 16 (risk class III: adults). TT was divided into 2 doses and administered on day minus 6.

Marrow was infused 36 hours after the last dose of CY. The median bone marrow nucleated cell dose was 3.8 × 108/kg of recipient weight (range, 1.8-11.6 × 108/kg). All patients received 3 mg/kg per day cyclosporine (CSP) intravenously from day −2 to day +30 and short-term methotrexate (MTX) for GVHD prophylaxis. The CSP schedule was switched to 9 mg/kg per day orally as soon as oral administration could be tolerated; from day +60 the dose was tapered until discontinuation at one year.

All patients were treated in positive-pressure isolation rooms and received nonabsorbable oral antibiotics and a low-bacteria diet. Supportive therapy, as well as prophylaxis and treatment of infections, was homogeneous among participating centers. Prophylaxis forPneumocystis carinii pneumonia was started after engraftment, with oral cotrimoxazole. CMV reactivation was monitored either by expression of the pp56 antigen or by direct PCR. Empirical broad-spectrum antibiotic therapy was started when patients became febrile, and antifungal therapy was added in the presence of either clinical evidence of fungal infection or fever persisting after 3 days of antibiotic therapy. All blood products administered after transplantation were irradiated with 30 Gy.

Neutrophil and platelet engraftment were defined as the first of 3 consecutive days with neutrophils more than 0.5 × 109/L and platelets more than 50 × 109/L, respectively. Acute and chronic GVHD were graded according to the Seattle criteria.40,41 

The first-choice drug for treatment of acute GVHD was steroids at a dosage of 2 to 10 mg/kg per day, depending on severity of GVHD.

Monitoring of chimerism

Chimerism was documented by in situ Y chromosome hybridization of either bone marrow or blood samples in sex-mismatched donor/recipient pairs, by analysis of a variable number of tandem repeat (VNTR) polymorphisms and by microsatellite analysis of bone marrow and/or blood samples in the case of sex-matched pairs. Analysis of chimerism and patterns of hemoglobin synthesis were first performed on peripheral blood and bone marrow aspirates on day +21 and repeated at biweekly intervals until day +60 to document engraftment of donor hematopoiesis.

Statistical evaluation

For continuous variables with a symmetric distribution, the results are expressed as medians and ranges. Comparison between groups was performed by Fisher exact test. Survival probability was estimated by the product-limit method of Kaplan and Meier.42 

Results

From November 1992 to May 2001, 185 patients with thalassemia activated a search for locating an unrelated donor at one of the 4 BMT centers involved in this study. For 35 patients (19%) a suitable donor was identified. There were 3 patients who declined the transplantation procedure and 32 (17%) who received an unrelated donor transplant. Positive result of donor search ranged from 32% for BMT centers in Sardinia to 12% for the other BMT centers, mainly dealing with patients belonging to mixed ethnical groups. The patients who did not find a donor with the required characteristics continued conventional therapy.

Immunogenetic selection of donor/recipient pairs performed at molecular level (Table 2) showed that 24 of the 32 donor/recipient pairs were completely identical for HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1, and -DQB1 loci. There were 5 pairs (pairs 4, 7, 14, 16, 28) mismatched for an HLA-Cw allele and one of these pairs (pair 4) also showed a molecular difference for an HLA-A allele. There were 3 pairs (pairs 6, 15, 24) that differed for an allelic variant of a class I HLA antigen at loci A, B, and B, respectively. At the DPB1 locus, 14 pairs shared both DP alleles, 13 were different for one allele, and 5 for both alleles.

There were 7 pairs (pairs 1, 3, 10, 12, 13, 20, 23) completely identical for 2 extended haplotypes and 15 pairs (pairs 2, 5, 7, 9, 11, 17, 18, 21, 22, 26, 27, 29, 30, 31, 32) that shared one extended haplotype (Table 2). Although the remaining 10 pairs did not share complete extended haplotypes, family segregation analysis performed in 5 cases in both donor and recipient showed haplotype identity in 3 cases (pairs 8, 19, 25). Only in one case (pair 4) was haplotype identity lacking, as demonstrated by family segregation analysis and by study of class III HLA antigens in both donor and recipient (data not shown).

Figure 1 shows Kaplan-Meier probabilities of survival, event-free survival, rejection, and nonrejection mortality for the 32 patients studied.

Fig. 1.

Kaplan-Meier probabilities of survival, thalassemia-free survival, nonrejection mortality, and rejections for 32 thalassemia patients who received transplants from HLA-matched unrelated donors (between parenthesis: 95% confidence limits at 2 years).

Fig. 1.

Kaplan-Meier probabilities of survival, thalassemia-free survival, nonrejection mortality, and rejections for 32 thalassemia patients who received transplants from HLA-matched unrelated donors (between parenthesis: 95% confidence limits at 2 years).

In 22 cases the transplantation was successful with complete allogeneic reconstitution (Table 1). In patients who showed allogeneic reconstitution, median time for granulocyte recovery was 16 days (range, 11-26 days), whereas median time for a self-sustained platelet recovery was 30 days (range, 16-60 days). The last death occurred on day +470 and the last episode of rejection was diagnosed on day +30. The median follow-up of surviving patients is 30 months (range, 7-109 months).

There were 6 patients who died from transplantation-related causes: one from hepatic veno-occlusive disease (day +17), one from CMV interstitial pneumonia (day +64), one from cerebral hemorrhage occurring as a complication of acute intestinal GVHD (day +66), one from cerebral hemorrhage related to liver failure (day +125), one from intestinal obstruction occurring as a complication of intestinal GVHD (day +269), and one from liver failure due to chronic GVHD (day +470). Although the difference was not statistically significant, 5 of the 6 patients who died belonged to risk-class III and only 1 to risk-class II. There were 4 deaths that occurred among 11 adults (age > 16 years) and 2 among 21 pediatric patients.

Grade II to IV acute GVHD developed in 11 cases (41%), and in 5 cases it was of grade III to IV (18%). Among the 24 evaluable patients, 6 (25%) developed chronic GVHD, which was limited in 4 cases and extensive in 2 cases (Table 1).

None of the 6 recipients who shared 2 HLA–extended haplotypes and had sustained donor engraftment developed grade II to IV acute GVHD (Table4), whereas in the remaining 21 evaluable patients who shared either a single or no extended haplotype, the overall occurrence of acute GVHD was 52% (P = .05; see also Table 4 for further details). A significant reduction of the incidence of acute GVHD was observed in the group of 14 patients who shared an identity for both DPB1 alleles with their donors, compared with the group of 18 patients who received bone marrow from a donor mismatched for either 1 or 2 DPB1 alleles (21% vs 61%, respectively,P = .05). Among the 14 patients (cases 1, 3, 10, 12, 17, 19, 23, 24, 26, 27, 28, 30, 31, 32) who achieved allogeneic engraftment without acute or chronic GVHD, 11 (78%) shared at least one extended haplotype with the donor and 8 (57%) were also identical at the DPB1 loci.

Table 4.

Impact of matching for HLA extended haplotypes

No. of patients No. of EH Alive and well Acute GVHD (II-IV) Chronic GVHD Rejection Death 
71.4 – – 14.2 14.2 
15 12 80.0 46.1 16.6 6.6 13.3 
10 50.0 62.5 57.1 20.0 30.0 
No. of patients No. of EH Alive and well Acute GVHD (II-IV) Chronic GVHD Rejection Death 
71.4 – – 14.2 14.2 
15 12 80.0 46.1 16.6 6.6 13.3 
10 50.0 62.5 57.1 20.0 30.0 

EH indicates extended haplotype.

Of the 22 patients who had a donor identical for at least one extended haplotype, 19 survived, 17 of them being transfusion- independent. Among the 10 recipients who did not share any extended haplotype with the donor, only 5 are alive without thalassemia, and 3 patients died.

In 4 cases, donor marrow was rejected with complete autologous reconstitution and return to pretransplantation clinical status. In 2 of these patients, rejection occurred after transient engraftment of donor cells. As mentioned above, 2 of 4 cases of rejection were observed in the first series of 4 patients conditioned with BU and CY alone, whereas only 2 cases of rejection occurred in the second series of 28 patients whose conditioning regimen included TT. One of the 2 patients in whom rejection was observed after documented engraftment (case 4) was the only one lacking haplotype identity.

Discussion

The majority of thalassemia patients do not have an HLA-identical donor within the family. For this reason, in recent years BMT centers engaged in the cure of hemoglobinopathies have been exposed to increasing questioning and pressure from both patients and families to explore the possibility of transplantation utilizing alternative donors.

Use of partially matched family donors carries a high risk of rejection, GVHD, and mortality, and has been confined to particular clinical situations.43 

Recently published reports indicate that the outcome of unrelated donor transplantations in patients with leukemia today is comparable with that of transplantations from identical family donors.16-18 This is due to the better compatibility between donor and recipient afforded by DNA methods and to the compensatory effect of a stronger graft-versus-leukemia over the increased risk of GVHD. In thalassemia, where GVHD represents a complication without benefit for the patient, it is mandatory to minimize the immunologic risks of BMT before accepting unrelated donor transplants as an established therapeutic option.

So far, there are only a few anecdotal reports44-46 on BMT from unrelated donors in thalassemia. This is the first large series of consecutive thalassemia patients reported from unrelated donors. In our cohort, rejection and mortality rates were 12.5% and 19%, respectively. Sixty-nine percent of our patients are alive with sustained engraftment of donor hematopoiesis, this leading to a projected thalassemia-free survival of 66%.

In our series, only one death was observed among 15 class I and class II patients (7%), the other 5 occurring among 17 class III patients (29%). In class III risk patients, transplantation-related mortality is high (32%) even when the donor is an HLA-identical sibling.3,47 Overall survival and thalassemia-free survival (93% and 80%, respectively) in the 15 patients of class I and class II risk groups were comparable with those obtained in transplantations from an HLA-identical family donor.1,2 

The relatively low incidence of acute and chronic GVHD (41% and 25%, respectively) confirms that a careful immunogenetic selection of donor/recipient pairs has an important role in reducing the incidence of this complication. In fact, the remarkable stability of the extended haplotypes21,36,48 and the data deriving from MLC studies49 support the hypothesis that 2 unrelated individuals sharing 2 HLA-extended haplotypes are nearly always practically HLA-genoidentical, just as if they had inherited the HLA haplotypes from the same parents. Therefore, it is reasonable to hypothesize that the histocompatibility differences between a pair of HLA-genoidentical siblings and a pair of unrelated individuals sharing 2 extended haplotypes exclusively reside in minor histocompatibility antigens (mHAg) located outside the HLA region. Moreover, haplotype matching, even when it is not for complete extended haplotypes, makes it possible to include parts of them (telomeric or centromeric portion of extended haplotypes) that are common in populations worldwide.50 

The method for donor/recipient selection reported here may require a prolonged search and reduce the probability of locating a suitable donor. However, it should be considered that the length of time from starting the search to performing the transplantation is not such a critical factor in thalassemia as it is, for example, in acute leukemia or congenital immune deficiencies. Patients with thalassemia receiving traditional medical treatment can maintain stable clinical conditions for a long period of time and therefore can wait until a donor with optimal immunogenetic characteristics is found. Moreover, it is possible that, due to the geographic distribution of thalassemia in selected areas, the probability of finding an unrelated identical donor may be higher than in the general population if in those areas large and representative marrow donor registries are established.36 

Data on the role of HLA antigen DP molecules in transplantation outcome are contradictory.51,52 So far, it is quite difficult to differentiate the role of DP molecules from that of other HLA molecules as this would require the availability of genoidentical donor/recipient pairs different at the DP locus for a rare event of crossing over. Alternatively, an optimal model for this type of evaluation is represented by unrelated donor/recipient pairs different at the DP locus but sharing 2 extended haplotypes. In our study, although the number of cases is small to draw definitive conclusions, a significant increase in the incidence of immunologic complications was observed in DPB1-mismatched recipients.

In our study, 2 of the 4 cases of rejection occurred in the first 4 patients conditioned with the standard BU-CY regimen. It is possible that the dose of BU (14 mg/kg) was not sufficient to guarantee blood drug levels capable of determining engraftment in BMT from MUD.53 However, since in adult thalassemia patients increasing the dosage of BU carries the risk of increased mortality and toxicity,54 in the second series of patients a third drug, TT, was added. TT at a dose of 10 mg/kg has been demonstrated to intensify both the myeloablative and immunosuppressive effect of the conditioning regimen, without a significant increase of extramedullary toxicity.55 Our results show that the protocol BU-TT-CY, with dosage of CY adjusted for risk class, was well tolerated.

Although obtained in a limited cohort of patients, our results show that BMT from unrelated donors, especially when identical for at least one extended haplotype, may offer a probability of success comparable to that offered by transplantations using HLA-identical family donors. It is therefore quite reasonable to consider this type of transplantation as an acceptable therapeutic approach in thalassemia, at least for patients who are not fully compliant with conventional treatment and do not yet show irreversible severe complications of iron overload, provided that careful immunogenetic selection of marrow donors is maintained.

We wish to thank Gruppo Italiano Trapianto Midollo Osseo (GITMO) for supporting this study and the Italian Bone Marrow Donor Registry (IBMDR) for donor search and identification.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

References

References
1
Giardini
C
Lucarelli
G
Bone marrow transplantation for beta-thalassemia.
Hematol Oncol Clin North Am.
13
1999
1059
1064
2
Lucarelli
G
Galimberti
M
Polchi
P
et al. 
Marrow transplantation in patients with thalassemia responsive to iron chelation therapy.
N Engl J Med.
329
1993
840
844
3
Lucarelli
G
Clift
RA
Galimberti
M
et al. 
Marrow transplantation for patients with thalassemia: results in class 3 patients.
Blood.
87
1996
2082
2088
4
Anasetti
C
Etzioni
R
Petersdorf
EW
Martin
PJ
Hansen
JA
Marrow transplantation from unrelated volunteer donors.
Ann Rev Med.
46
1995
169
179
5
Olivieri
NF
The β-thalassemia.
New Engl J Med.
34
1999
99
109
6
Cao
A
Moi
P
Genetic modifying factors in beta-thalassemia.
Clin Chem Lab Med.
58
2000
123
132
7
Olivieri
NF
Brittenham
GM
Iron-chelating therapy and the treatment of thalassemia.
Blood.
89
1997
739
761
8
Zurlo
MG
De Stefano
P
Borgna Pignatti
C
et al. 
Survival and causes of death in thalassemia major.
Lancet.
2
1989
27
30
9
Olivieri
N
Nathan
DG
MacMillan
JH
et al. 
Survival in medically treated patients with homozygous beta-thalassemia.
New Engl Med.
331
1994
574
578
10
Kernan
NA
Bartsh
G
Ash
RC
et al. 
Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.
New Engl J Med.
328
1993
593
602
11
Filipovich
AH
Shapiro
RS
Ramsay
NKC
et al. 
Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies.
Blood.
80
1992
270
276
12
Davies
SM
Khan
S
Wagner
JE
et al. 
Unrelated donor bone marrow transplantation for Fanconi anemia.
Bone Marrow Transplant.
17
1996
43
47
13
Santamaria
P
Reinsmoen
NL
Lindstrom
AL
et al. 
Frequent HLA class I and DP sequence mismatchs in serologically (HLA-A, HLA-B, HLA-DR) and molecularly (HLA- DRB1, HLA-DQA1, HLA-DQB1) HLA-identical unrelated bone marrow transplant pairs.
Blood.
83
1994
280
287
14
Anasetti
C
Hansen
JA
Effect of HLA incompatibility in marrow transplantation for patients from unrelated donors and mismatched related donors.
Trasf Sci.
15
1994
221
230
15
Petersdorf
EW
Longton
JM
Anasetti
C
et al. 
Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors.
Blood.
89
1997
1818
1823
16
Hongen
S
Krance
AR
Bowman
LC
et al. 
Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow transplantation in children with leukaemia.
Lancet.
350
1997
767
771
17
Hansen
JA
Gooley
TA
Martin
PJ
et al. 
Bone marrow transplants from unrelated donors for patients with chronic myeloid leukaemia.
New Engl J Med.
228
1998
962
968
18
Davies
SM
Kollman
C
Anasetti
C
et al. 
Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program.
Blood.
96
2000
4096
4121
19
Speiser
DE
Tiercy
JM
Rufer
N
et al. 
High resolution HLA typing associated with decreased mortality after unrelated bone marrow transplantation.
Blood.
87
1996
4455
4462
20
Petersdorf
EW
Gooley
TA
Anasetti
C
et al. 
Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient.
Blood.
92
1998
3515
3520
21
Degli Esposti
MA
Leelayuwat
C
Daly
LN
et al. 
Updated characterization of the ancestral haplotypes using the fourth Asia-Oceania Histocompatibility Workshop panel.
Hum Immunol.
44
1995
12
18
22
Christiansen
FT
Witt
CS
Dawkins
RL
Questions in marrow matching: the implications of ancestral haplotypes for routine practice.
Bone Marrow Transplant.
8
1991
83
86
23
Tay
GK
Christiansen
FT
Charron
D
et al. 
Matching for MHC haplotypes results in improved survival following unrelated bone marrow transplantation.
Bone Marrow Transplant.
15
1995
381
385
24
La Nasa
G
Vacca
A
Pizzati
A
et al. 
Role of HLA extended haplotypes in unrelated bone marrow transplantation.
Bone Marrow Transplant.
19(suppl 1)
1997
186
189
25
Lucarelli
G
Giardini
C
Angelucci
E
Bone marrow transplantation in thalassemia.
Blood Stem Cell Transplantation.
Winter
JN
1997
305
315
Kluwer Academic
Boston, MA
26
Muretto
P
Angelucci
E
Del Fiasco
S
Lucarelli
G
Reversal features of hepatic haemosiderosis and haemochromatosis in thalassemia after bone marrow transplantation.
Prog Clin Biol Res.
309
1989
299
314
27
Scheltinga
SA
Johnston-Dow
LA
White
CB
et al. 
A generic sequencing based typing approach for the identification of HLA-A diversity.
Hum Immunol.
57
1997
120
128
28
Pozzi
S
Longo
A
Ferrara
GB
HLA-B locus sequence-based typing.
Tissue Antigens.
53
1999
275
281
29
Van Der Vlies
SA
Voorter
CEM
Van Den Berg-Loonen
EM
A reliable and efficient high resolution typing method for HLA-C using sequence-based typing.
Tissue Antigens.
52
1998
558
568
30
Voorter
CEM
Rozemuller
EH
De Bruyn-Geraets
D
et al. 
Comparison of DRB sequence-based typing using different strategies.
Tissue Antigens.
49
1997
471
476
31
Bodmer
JG
Marsh
SG
Albert
ED
et al. 
Nomenclature for factors of the HLA system, 1998.
Tissue Antigens.
53
1999
407
446
32
Awdeh
AL
Alper
CA
Inherited structural polymorphism of the fourth component of human complement.
Proc Natl Acad Sci U S A.
77
1980
3576
3580
33
Alper
CA
Boenish
T
Watson
L
Genetic polymorphism in human glycine-rich-beta lipoprotein.
J Exp Med.
135
1972
68
80
34
Dawkins
R
Leelayuwat
C
Gauderi
S
et al. 
Genomics of the major histocompatibility complex: haplotypes, duplication, retrovires and disease.
Immunol Rev.
167
1999
275
304
35
Rendine
S
Borelli
I
Barbanti
M
Roggero
S
Curtoni
ES
HLA polymorphisms in Italian bone marrow donors: a regional analysis.
Tissue Antigens.
52
1998
135
146
36
Contu
L
Arras
M
Carcassi
C
La Nasa
G
Mulargia
M
HLA structure of the Sardinian population: a haplotype study of 551 families.
Tissue Antigens.
40
1992
165
174
37
Degli-Esposti
MA
Griffiths
MSJ
Daly
LN
et al. 
Characterisation of 4OHW cell line panel including data for the 10 IHW panel.
Hum Immunol.
38
1993
3
16
38
Imanishi
T
Akaza
T
Kimura
A
Tokunaga
K
Gojobori
T
Allele and haplotype frequences for HLA and complement loci in various ethnic groups.
Proceedings of the 11th IHW
Tsuji
K
Aizawa
M
Sasazuki
T
I
1991
1065
1220
Oxford University Press
Yokohama, Japan
39
Boucher
K
Mori
M
Milford
E
Beatty
PG
Estimation of HLA-A-B-DR haplotype frequencies in five racial groups represented in the NMDP donor file.
HLA 1998, American Society for Histocompatibility and Immunogenetics.
Gjerston
DW
Terasaki
PI
1998
57
78
American Society for Histocompatibility and Immunogenetics
Lenexa
40
Thomas
ED
Storb
R
Clift
RA
et al. 
Bone marrow transplantation.
N Engl J Med.
292
1975
832
843
41
Shulman
HM
Sullivan
KM
Weiden
PL
et al. 
Chronic graft-versus-host syndrome in man: a long-term clinico-pathologic study of 20 Seattle patients.
Am J Med.
69
1980
204
217
42
Kaplan
ER
Meier
P
Non parametric estimation from incomplete observations.
J Am Stat Assoc.
53
1958
457
481
43
Gaziev
D
Galimberti
M
Lucarelli
G
et al. 
Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants.
Bone Marrow Transplant.
25
2000
815
821
44
Contu
L
La Nasa
G
Arras
M
et al. 
Successful unrelated bone marrow transplantation in thalassemia.
Bone Marrow Transplant.
13
1994
329
331
45
Sullivan
KM
Anasetti
C
Horowitz
M
et al. 
Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia.
Ann NY Acad Sci.
850
1998
312
324
46
De Stefano
P
Zecca
M
Giorgiani
G
Perotti
C
Giraldi
E
Locatelli
F
Resolution of immune hemolytic anemia with allogeneic bone marrow transplantation after an unsuccessful autograft.
Br J Haematol.
106
1999
1063
1064
47
Lucarelli
G
Galimberti
M
Giardini
C
et al. 
Bone marrow transplantation in thalassemia.
Ann NY Acad Sci.
850
1998
270
275
48
Ramsbottom
D
Carcassi
C
de Solages
H
et al. 
MHC haplotypes including eight microsatellites in French Basques and in Sardinian.
Genetic Diversity of HLA: Functional and Medical Implications. Proceedings of the 12th IHW
Charron
D
II
1997
178
180
EDK
Paris, France
49
Awdeh
ZL
Alper
CA
Eynon
E
et al. 
Unrelated individuals matched for MHC extended haplotypes and HLA identical siblings shows comparable responses in MLC.
Lancet.
2
1985
853
856
50
Bodmer
J
Cambon-Thomsem
A
Hors
J
Piazza
A
Sanchez-Mazas
A
Anthropology: contribution of HLA.
Genetic Diversity of HLA: Functional and Medical Implications. Proceedings of the 12th IHW
Charron
D
I
1997
269
284
EDK
Paris, France
51
Moreau
P
Cesbron
A
HLA-DP and allogeneic bone marrow transplantation.
Bone Marrow Transplant.
13
1994
675
681
52
Petersdorf
EW
Gooley
T
Malkki
M
et al. 
The biological significance of HLA-DP gene variation in haematopoietic cell transplantation.
Br J Haematol.
112
2001
988
994
53
Slattery
JT
Sanders
JE
Buckner
CD
et al. 
Graft rejection and toxicity following bone marrow transplantation in relation to Busulphan pharmacokinetics.
Bone Marrow Transplant.
16
1995
31
34
54
Lucarelli
G
Galimberti
M
Delfini
C
et al. 
Marrow transplantation for thalassemia following busulphan and cyclophosphamide.
Lancet.
1
1985
1355
1357
55
Zecca
M
Pession
A
Messina
C
et al. 
TBI, thiotepa and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukaemia in 1st or 2nd remission given bone marrow transplantation from HLA-identical siblings.
J Clin Oncol.
17
1999
1838
1846

Author notes

Giorgio La Nasa, Centro Trapianti Midollo Osseo, Ospedale “Binaghi” ASL no. 8, Via Is Guadazzonis, 3, 09126 Cagliari, Italy; e-mail: lanasa@tiscalinet.it.